DataMeds AI has announced a series of developments at its pharmaceuticals subsidiary, Corexa Health, saying the business has secured registration to offer both oral and injectable GLP‑1 agonist drugs and completed integration of its online pharmacy into a newly launched health app.
What the company reported
In a statement, DataMeds AI said Corexa Pharmacy achieved qualitative and quantitative milestones positioning it to be a growth engine in the second half of 2026. The company reported:
- registration with TrumpRx to provide patients access to oral GLP‑1 agonists, citing examples of Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy;
- availability of injectable GLP‑1 agonist drugs;
- launch of an online store, CorexaRx.com/Store;
- integration of that store into the Health Lives Here app (available via the Apple App Store and Google Play); and
- commercial availability of companion medical foods and supplements, including Forzet and Galectovid, plus a dietary supplement called Tollovid.
DataMeds AI also said revenue “stabilised above $600,000 for July 2026” amid a rebrand and the planned expansion of services through the Health Lives Here app, which was introduced at the 2026 Pro Football Hall of Fame Game and initially made available to former NFL players.
How the service will work
The company described an integrated pathway through the app whereby patients can book a telemedicine visit, receive a prescription or refills for GLP‑1 therapies and medical foods, and monitor health data while on therapy. DataMeds AI highlighted its Health IT platform, EinsteinRx, and a blockchain-enabled smart contracts platform, PharmacyChain, as underlying technology supporting the service.
| Milestone | Detail |
|---|---|
| Registration | TrumpRx registration to offer oral GLP‑1s (example products cited) |
| Product availability | Oral and injectable GLP‑1 agonists; medical foods Forzet & Galectovid; Tollovid supplement |
| Distribution channel | CorexaRx.com/Store integrated into Health Lives Here app |
| Commercial metric | Revenue stabilised above $600,000 for July 2026 |
Context and implications
GLP‑1 agonists have become central to treatment for type 2 diabetes and weight management. The announcement speaks to two broader trends in global healthcare: the digitisation of pharmacy services through telemedicine platforms, and the rapid commercialisation and wider availability of GLP‑1 therapies.
Online prescribing and dispensing models can improve access for some patients but also raise questions for regulators about clinical oversight, safe prescribing, supply chain integrity and pharmacovigilance. The use of companion medical foods and supplements alongside GLP‑1 therapy is marketed as complementary management of nutrition and muscle mass, but evidence and clinical guidance on combined use vary by product and indication.
DataMeds AI described proprietary technology — EinsteinRx and PharmacyChain — as the backbone for enabling telemedicine, prescription fulfilment and data monitoring. The company framed the Health Lives Here app as a way to centralise care pathways, facilitate follow-up and enable data collection while patients are on therapy.
What to watch next
- Regulatory scrutiny: how pharmaceutical regulators and professional bodies assess online supply of GLP‑1s and whether further safeguards will be required.
- Clinical oversight: the degree of in-person assessment and ongoing monitoring provided via the telemedicine model.
- Patient safety and reporting: mechanisms for adverse event reporting and quality assurance across the digital pharmacy and fulfilment chain.
This development underlines the expanding role of digital platforms in medication access. Patients considering GLP‑1 therapy should consult a qualified clinician at their clinic or hospital to discuss suitability, potential side effects and monitoring requirements rather than rely solely on online information or apps.
Data in this report are taken from the company’s update and related disclosures, which described the milestones and revenue figures cited above.
